Zacks: Analysts Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00

Brokerages expect that Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) will post sales of $280,000.00 for the current quarter, Zacks reports. Four analysts have made estimates for Galmed Pharmaceuticals’ earnings, with estimates ranging from $250,000.00 to $300,000.00. Galmed Pharmaceuticals reported sales of $270,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 3.7%. The business is expected to report its next quarterly earnings results on Thursday, March 22nd.

On average, analysts expect that Galmed Pharmaceuticals will report full-year sales of $280,000.00 for the current year, with estimates ranging from $800,000.00 to $1.10 million. For the next fiscal year, analysts expect that the firm will post sales of $980,000.00 per share, with estimates ranging from $550,000.00 to $1.20 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that that provide coverage for Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.04. Galmed Pharmaceuticals had a negative return on equity of 167.83% and a negative net margin of 1,242.49%.

A number of brokerages have issued reports on GLMD. Roth Capital began coverage on Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $32.00 price objective for the company. ValuEngine cut Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research cut Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Maxim Group set a $14.00 price objective on Galmed Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, December 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Galmed Pharmaceuticals in a research note on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.20.

A hedge fund recently raised its stake in Galmed Pharmaceuticals stock. 683 Capital Management LLC lifted its holdings in Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) by 9.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 549,295 shares of the biopharmaceutical company’s stock after purchasing an additional 49,295 shares during the quarter. 683 Capital Management LLC owned 4.31% of Galmed Pharmaceuticals worth $5,021,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 9.80% of the company’s stock.

Galmed Pharmaceuticals (GLMD) opened at $10.18 on Monday. The stock has a market capitalization of $129.63, a price-to-earnings ratio of -9.17 and a beta of 2.42. Galmed Pharmaceuticals has a one year low of $3.90 and a one year high of $12.22.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/05/zacks-analysts-expect-galmed-pharmaceuticals-ltd-glmd-will-announce-quarterly-sales-of-280000-00.html.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply